ACADIA to Host Conference Call and Webcast on Tuesday, February 27,2018, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Feb. 20, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will report its financial results for the fourthquarter and year ended December 31, 2017 on Tuesday, February 27, 2018,after the U.S. financial markets close. ACADIA's management will host aconference call and webcast on Tuesday, February 27, 2018, at 5:00 p.m.Eastern Time to discuss ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 forparticipants in the United States or Canada and 830-865-2550 forinternational callers (reference passcode 8377668). A telephone replayof the conference call may be accessed through March 13, 2018 by dialing855-859-2056 for callers in the United States or Canada and 404-537-3406for international callers (reference passcode 8377668). The conferencecall also will be webcast live on ACADIA’s website, www.acadia-pharm.comunder the investors section and will be archived there until March 13,2018.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceuticalcompany focused on the development and commercialization of innovativemedicines that address unmet medical needs in central nervous systemdisorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press releasethat are not strictly historical in nature are forward-lookingstatements. These statements include but are not limited to statementsrelated to the progress and timing of ACADIA’s drug discovery anddevelopment programs, and the benefits to be derived from NUPLAZID®(pimavanserin) and ACADIA’s product candidates. These statements areonly predictions based on current information and expectations andinvolve a number of risks and uncertainties. Actual events or resultsmay differ materially from those projected in any of such statements dueto various factors, including the risks and uncertainties inherent indrug discovery, development, approval and commercialization, and incollaborations with others, and the fact that past results of clinicaltrials may not be indicative of future trial results. For a discussionof these and other factors, please refer to ACADIA’s annual report onForm 10-K for the year ended December 31, 2016 as well as ACADIA’ssubsequent filings with the Securities and Exchange Commission. You arecautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, InvestorRelations
(858) 558-2871
ir@acadia-pharm.com